nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—CYP2C19—Prednisone—multiple sclerosis	0.0354	0.346	CbGbCtD
Nilutamide—CYP2C8—Dexamethasone—multiple sclerosis	0.0263	0.258	CbGbCtD
Nilutamide—CYP2C19—Dexamethasone—multiple sclerosis	0.0221	0.216	CbGbCtD
Nilutamide—CYP2C9—Dexamethasone—multiple sclerosis	0.0184	0.18	CbGbCtD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.0162	0.134	CbGpPWpGaD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.0162	0.134	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—HNRNPA1—multiple sclerosis	0.00391	0.0324	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.00351	0.0291	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—ZMIZ1—multiple sclerosis	0.00309	0.0256	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptors—PGR—multiple sclerosis	0.00248	0.0206	CbGpPWpGaD
Nilutamide—Enzalutamide—ALB—multiple sclerosis	0.00239	1	CrCbGaD
Nilutamide—AR—Androgen receptor signaling pathway—ZMIZ1—multiple sclerosis	0.00228	0.0189	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00221	0.0183	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00221	0.0183	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00203	0.00262	CcSEcCtD
Nilutamide—Rhinitis—Triamcinolone—multiple sclerosis	0.00203	0.00261	CcSEcCtD
Nilutamide—Rhinitis—Methylprednisolone—multiple sclerosis	0.00202	0.00261	CcSEcCtD
Nilutamide—Hypertension—Mitoxantrone—multiple sclerosis	0.00201	0.0026	CcSEcCtD
Nilutamide—Chest pain—Mitoxantrone—multiple sclerosis	0.00198	0.00256	CcSEcCtD
Nilutamide—Diarrhoea—Cladribine—multiple sclerosis	0.00198	0.00256	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00196	0.0163	CbGpPWpGaD
Nilutamide—Discomfort—Mitoxantrone—multiple sclerosis	0.00196	0.00253	CcSEcCtD
Nilutamide—Visual impairment—Methylprednisolone—multiple sclerosis	0.00194	0.00251	CcSEcCtD
Nilutamide—Feeling abnormal—Azathioprine—multiple sclerosis	0.00194	0.0025	CcSEcCtD
Nilutamide—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00192	0.00248	CcSEcCtD
Nilutamide—Dizziness—Cladribine—multiple sclerosis	0.00191	0.00247	CcSEcCtD
Nilutamide—Oedema—Mitoxantrone—multiple sclerosis	0.0019	0.00246	CcSEcCtD
Nilutamide—Shock—Mitoxantrone—multiple sclerosis	0.00187	0.00242	CcSEcCtD
Nilutamide—Abdominal pain—Azathioprine—multiple sclerosis	0.00186	0.0024	CcSEcCtD
Nilutamide—Body temperature increased—Azathioprine—multiple sclerosis	0.00186	0.0024	CcSEcCtD
Nilutamide—Vomiting—Cladribine—multiple sclerosis	0.00184	0.00237	CcSEcCtD
Nilutamide—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00184	0.00237	CcSEcCtD
Nilutamide—Erectile dysfunction—Prednisone—multiple sclerosis	0.00184	0.00237	CcSEcCtD
Nilutamide—Rash—Cladribine—multiple sclerosis	0.00182	0.00236	CcSEcCtD
Nilutamide—Dermatitis—Cladribine—multiple sclerosis	0.00182	0.00235	CcSEcCtD
Nilutamide—Anorexia—Mitoxantrone—multiple sclerosis	0.00181	0.00234	CcSEcCtD
Nilutamide—Headache—Cladribine—multiple sclerosis	0.00181	0.00234	CcSEcCtD
Nilutamide—Weight decreased—Prednisone—multiple sclerosis	0.0018	0.00233	CcSEcCtD
Nilutamide—Hyperglycaemia—Prednisone—multiple sclerosis	0.0018	0.00232	CcSEcCtD
Nilutamide—Ill-defined disorder—Prednisolone—multiple sclerosis	0.00177	0.00229	CcSEcCtD
Nilutamide—Depression—Prednisone—multiple sclerosis	0.00177	0.00229	CcSEcCtD
Nilutamide—Visual impairment—Betamethasone—multiple sclerosis	0.00177	0.00228	CcSEcCtD
Nilutamide—Visual impairment—Dexamethasone—multiple sclerosis	0.00177	0.00228	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—VDR—multiple sclerosis	0.00174	0.0144	CbGpPWpGaD
Nilutamide—Malaise—Prednisolone—multiple sclerosis	0.00172	0.00223	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00172	0.0143	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00172	0.0143	CbGpPWpGaD
Nilutamide—Nausea—Cladribine—multiple sclerosis	0.00172	0.00222	CcSEcCtD
Nilutamide—Syncope—Prednisolone—multiple sclerosis	0.00171	0.00221	CcSEcCtD
Nilutamide—Paraesthesia—Mitoxantrone—multiple sclerosis	0.00171	0.0022	CcSEcCtD
Nilutamide—Back pain—Triamcinolone—multiple sclerosis	0.0017	0.0022	CcSEcCtD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.0017	0.0141	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.0017	0.0141	CbGpPWpGaD
Nilutamide—Dyspnoea—Mitoxantrone—multiple sclerosis	0.0017	0.00219	CcSEcCtD
Nilutamide—Loss of consciousness—Prednisolone—multiple sclerosis	0.00168	0.00217	CcSEcCtD
Nilutamide—Dyspepsia—Mitoxantrone—multiple sclerosis	0.00167	0.00216	CcSEcCtD
Nilutamide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00165	0.00213	CcSEcCtD
Nilutamide—Hypertension—Prednisolone—multiple sclerosis	0.00165	0.00213	CcSEcCtD
Nilutamide—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00163	0.00211	CcSEcCtD
Nilutamide—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.00163	0.0021	CcSEcCtD
Nilutamide—Pain—Mitoxantrone—multiple sclerosis	0.00163	0.0021	CcSEcCtD
Nilutamide—Constipation—Mitoxantrone—multiple sclerosis	0.00163	0.0021	CcSEcCtD
Nilutamide—Alopecia—Dexamethasone—multiple sclerosis	0.00162	0.00209	CcSEcCtD
Nilutamide—Alopecia—Betamethasone—multiple sclerosis	0.00162	0.00209	CcSEcCtD
Nilutamide—Diarrhoea—Azathioprine—multiple sclerosis	0.00161	0.00208	CcSEcCtD
Nilutamide—Discomfort—Prednisolone—multiple sclerosis	0.00161	0.00208	CcSEcCtD
Nilutamide—Malaise—Triamcinolone—multiple sclerosis	0.00159	0.00205	CcSEcCtD
Nilutamide—Malaise—Methylprednisolone—multiple sclerosis	0.00158	0.00204	CcSEcCtD
Nilutamide—Syncope—Triamcinolone—multiple sclerosis	0.00158	0.00204	CcSEcCtD
Nilutamide—Syncope—Methylprednisolone—multiple sclerosis	0.00157	0.00203	CcSEcCtD
Nilutamide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00157	0.00202	CcSEcCtD
Nilutamide—Oedema—Prednisolone—multiple sclerosis	0.00156	0.00201	CcSEcCtD
Nilutamide—Dizziness—Azathioprine—multiple sclerosis	0.00156	0.00201	CcSEcCtD
Nilutamide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00156	0.00201	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.00155	0.002	CcSEcCtD
Nilutamide—Loss of consciousness—Triamcinolone—multiple sclerosis	0.00155	0.00199	CcSEcCtD
Nilutamide—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.00154	0.00199	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00154	0.0127	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00154	0.0127	CbGpPWpGaD
Nilutamide—Shock—Prednisolone—multiple sclerosis	0.00154	0.00198	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—multiple sclerosis	0.00153	0.00198	CcSEcCtD
Nilutamide—Cough—Triamcinolone—multiple sclerosis	0.00153	0.00198	CcSEcCtD
Nilutamide—Hypertension—Triamcinolone—multiple sclerosis	0.00152	0.00196	CcSEcCtD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00152	0.0126	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00152	0.0126	CbGpPWpGaD
Nilutamide—Hypertension—Methylprednisolone—multiple sclerosis	0.00151	0.00196	CcSEcCtD
Nilutamide—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00151	0.00195	CcSEcCtD
Nilutamide—Body temperature increased—Mitoxantrone—multiple sclerosis	0.0015	0.00194	CcSEcCtD
Nilutamide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.0015	0.00194	CcSEcCtD
Nilutamide—Vomiting—Azathioprine—multiple sclerosis	0.0015	0.00193	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.0015	0.0124	CbGpPWpGaD
Nilutamide—Pneumonia—Methotrexate—multiple sclerosis	0.00149	0.00193	CcSEcCtD
Nilutamide—Rash—Azathioprine—multiple sclerosis	0.00148	0.00191	CcSEcCtD
Nilutamide—Dermatitis—Azathioprine—multiple sclerosis	0.00148	0.00191	CcSEcCtD
Nilutamide—Depression—Methotrexate—multiple sclerosis	0.00148	0.00191	CcSEcCtD
Nilutamide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00148	0.00191	CcSEcCtD
Nilutamide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00148	0.00191	CcSEcCtD
Nilutamide—Discomfort—Triamcinolone—multiple sclerosis	0.00148	0.00191	CcSEcCtD
Nilutamide—Discomfort—Methylprednisolone—multiple sclerosis	0.00148	0.0019	CcSEcCtD
Nilutamide—Headache—Azathioprine—multiple sclerosis	0.00147	0.0019	CcSEcCtD
Nilutamide—Dry mouth—Triamcinolone—multiple sclerosis	0.00146	0.00189	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.00146	0.0121	CbGpPWpGaD
Nilutamide—Malaise—Betamethasone—multiple sclerosis	0.00144	0.00186	CcSEcCtD
Nilutamide—Malaise—Dexamethasone—multiple sclerosis	0.00144	0.00186	CcSEcCtD
Nilutamide—Oedema—Triamcinolone—multiple sclerosis	0.00144	0.00185	CcSEcCtD
Nilutamide—Syncope—Dexamethasone—multiple sclerosis	0.00143	0.00185	CcSEcCtD
Nilutamide—Syncope—Betamethasone—multiple sclerosis	0.00143	0.00185	CcSEcCtD
Nilutamide—Sweating—Methotrexate—multiple sclerosis	0.00142	0.00184	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—multiple sclerosis	0.00142	0.00183	CcSEcCtD
Nilutamide—Shock—Triamcinolone—multiple sclerosis	0.00141	0.00182	CcSEcCtD
Nilutamide—Insomnia—Prednisolone—multiple sclerosis	0.00141	0.00182	CcSEcCtD
Nilutamide—Alopecia—Prednisone—multiple sclerosis	0.00141	0.00182	CcSEcCtD
Nilutamide—Shock—Methylprednisolone—multiple sclerosis	0.00141	0.00182	CcSEcCtD
Nilutamide—Loss of consciousness—Dexamethasone—multiple sclerosis	0.0014	0.00181	CcSEcCtD
Nilutamide—Loss of consciousness—Betamethasone—multiple sclerosis	0.0014	0.00181	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.0014	0.0116	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.0014	0.0116	CbGpPWpGaD
Nilutamide—Paraesthesia—Prednisolone—multiple sclerosis	0.0014	0.00181	CcSEcCtD
Nilutamide—Nausea—Azathioprine—multiple sclerosis	0.0014	0.0018	CcSEcCtD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.0014	0.0116	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.0014	0.0116	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00139	0.00179	CcSEcCtD
Nilutamide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00138	0.00179	CcSEcCtD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00138	0.0115	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00138	0.0115	CbGpPWpGaD
Nilutamide—Hypertension—Betamethasone—multiple sclerosis	0.00138	0.00178	CcSEcCtD
Nilutamide—Hypertension—Dexamethasone—multiple sclerosis	0.00138	0.00178	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.00137	0.0114	CbGpPWpGaD
Nilutamide—Asthenia—Mitoxantrone—multiple sclerosis	0.00136	0.00176	CcSEcCtD
Nilutamide—Discomfort—Betamethasone—multiple sclerosis	0.00134	0.00173	CcSEcCtD
Nilutamide—Discomfort—Dexamethasone—multiple sclerosis	0.00134	0.00173	CcSEcCtD
Nilutamide—Pain—Prednisolone—multiple sclerosis	0.00133	0.00172	CcSEcCtD
Nilutamide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.00132	0.0017	CcSEcCtD
Nilutamide—Urethral disorder—Methotrexate—multiple sclerosis	0.00131	0.00169	CcSEcCtD
Nilutamide—Oedema—Betamethasone—multiple sclerosis	0.0013	0.00168	CcSEcCtD
Nilutamide—Oedema—Dexamethasone—multiple sclerosis	0.0013	0.00168	CcSEcCtD
Nilutamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.0013	0.00168	CcSEcCtD
Nilutamide—Insomnia—Triamcinolone—multiple sclerosis	0.0013	0.00168	CcSEcCtD
Nilutamide—Insomnia—Methylprednisolone—multiple sclerosis	0.0013	0.00167	CcSEcCtD
Nilutamide—Ill-defined disorder—Prednisone—multiple sclerosis	0.00129	0.00166	CcSEcCtD
Nilutamide—Paraesthesia—Triamcinolone—multiple sclerosis	0.00129	0.00166	CcSEcCtD
Nilutamide—Feeling abnormal—Prednisolone—multiple sclerosis	0.00129	0.00166	CcSEcCtD
Nilutamide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00129	0.00166	CcSEcCtD
Nilutamide—Visual impairment—Methotrexate—multiple sclerosis	0.00129	0.00166	CcSEcCtD
Nilutamide—Anaemia—Prednisone—multiple sclerosis	0.00128	0.00166	CcSEcCtD
Nilutamide—Shock—Betamethasone—multiple sclerosis	0.00128	0.00165	CcSEcCtD
Nilutamide—Shock—Dexamethasone—multiple sclerosis	0.00128	0.00165	CcSEcCtD
Nilutamide—Dyspnoea—Triamcinolone—multiple sclerosis	0.00128	0.00165	CcSEcCtD
Nilutamide—Dyspepsia—Triamcinolone—multiple sclerosis	0.00126	0.00163	CcSEcCtD
Nilutamide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00126	0.00163	CcSEcCtD
Nilutamide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00126	0.00162	CcSEcCtD
Nilutamide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00126	0.00162	CcSEcCtD
Nilutamide—Malaise—Prednisone—multiple sclerosis	0.00125	0.00162	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00125	0.0103	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00125	0.0103	CbGpPWpGaD
Nilutamide—Syncope—Prednisone—multiple sclerosis	0.00125	0.00161	CcSEcCtD
Nilutamide—Anorexia—Dexamethasone—multiple sclerosis	0.00124	0.0016	CcSEcCtD
Nilutamide—Anorexia—Betamethasone—multiple sclerosis	0.00124	0.0016	CcSEcCtD
Nilutamide—Pain—Triamcinolone—multiple sclerosis	0.00123	0.00158	CcSEcCtD
Nilutamide—Loss of consciousness—Prednisone—multiple sclerosis	0.00122	0.00158	CcSEcCtD
Nilutamide—Vomiting—Mitoxantrone—multiple sclerosis	0.00121	0.00156	CcSEcCtD
Nilutamide—Hypertension—Prednisone—multiple sclerosis	0.0012	0.00155	CcSEcCtD
Nilutamide—Rash—Mitoxantrone—multiple sclerosis	0.0012	0.00155	CcSEcCtD
Nilutamide—Dermatitis—Mitoxantrone—multiple sclerosis	0.0012	0.00155	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.00119	0.0099	CbGpPWpGaD
Nilutamide—Headache—Mitoxantrone—multiple sclerosis	0.00119	0.00154	CcSEcCtD
Nilutamide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00118	0.00153	CcSEcCtD
Nilutamide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00118	0.00152	CcSEcCtD
Nilutamide—Alopecia—Methotrexate—multiple sclerosis	0.00118	0.00152	CcSEcCtD
Nilutamide—Insomnia—Betamethasone—multiple sclerosis	0.00118	0.00152	CcSEcCtD
Nilutamide—Insomnia—Dexamethasone—multiple sclerosis	0.00118	0.00152	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00117	0.00151	CcSEcCtD
Nilutamide—Paraesthesia—Betamethasone—multiple sclerosis	0.00117	0.00151	CcSEcCtD
Nilutamide—Paraesthesia—Dexamethasone—multiple sclerosis	0.00117	0.00151	CcSEcCtD
Nilutamide—Discomfort—Prednisone—multiple sclerosis	0.00117	0.00151	CcSEcCtD
Nilutamide—Dyspepsia—Dexamethasone—multiple sclerosis	0.00115	0.00148	CcSEcCtD
Nilutamide—Dyspepsia—Betamethasone—multiple sclerosis	0.00115	0.00148	CcSEcCtD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00114	0.00942	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00114	0.00942	CbGpPWpGaD
Nilutamide—Body temperature increased—Triamcinolone—multiple sclerosis	0.00113	0.00146	CcSEcCtD
Nilutamide—Oedema—Prednisone—multiple sclerosis	0.00113	0.00146	CcSEcCtD
Nilutamide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00113	0.00146	CcSEcCtD
Nilutamide—Decreased appetite—Betamethasone—multiple sclerosis	0.00113	0.00146	CcSEcCtD
Nilutamide—Decreased appetite—Dexamethasone—multiple sclerosis	0.00113	0.00146	CcSEcCtD
Nilutamide—Nausea—Mitoxantrone—multiple sclerosis	0.00113	0.00146	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00112	0.00145	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00112	0.00145	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00112	0.00932	CbGpPWpGaD
Nilutamide—Back pain—Methotrexate—multiple sclerosis	0.00112	0.00145	CcSEcCtD
Nilutamide—Shock—Prednisone—multiple sclerosis	0.00112	0.00144	CcSEcCtD
Nilutamide—Pain—Betamethasone—multiple sclerosis	0.00111	0.00144	CcSEcCtD
Nilutamide—Pain—Dexamethasone—multiple sclerosis	0.00111	0.00144	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.0011	0.00916	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.0011	0.00916	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Prednisone—multiple sclerosis	0.0011	0.00141	CcSEcCtD
Nilutamide—Anorexia—Prednisone—multiple sclerosis	0.00108	0.0014	CcSEcCtD
Nilutamide—Ill-defined disorder—Methotrexate—multiple sclerosis	0.00108	0.00139	CcSEcCtD
Nilutamide—Anaemia—Methotrexate—multiple sclerosis	0.00107	0.00139	CcSEcCtD
Nilutamide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00107	0.00139	CcSEcCtD
Nilutamide—Feeling abnormal—Betamethasone—multiple sclerosis	0.00107	0.00139	CcSEcCtD
Nilutamide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00106	0.00137	CcSEcCtD
Nilutamide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00106	0.00137	CcSEcCtD
Nilutamide—Malaise—Methotrexate—multiple sclerosis	0.00105	0.00135	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—multiple sclerosis	0.00104	0.00134	CcSEcCtD
Nilutamide—Dizziness—Prednisolone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Asthenia—Triamcinolone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Body temperature increased—Dexamethasone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Abdominal pain—Betamethasone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Body temperature increased—Betamethasone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Abdominal pain—Dexamethasone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Asthenia—Methylprednisolone—multiple sclerosis	0.00103	0.00133	CcSEcCtD
Nilutamide—Insomnia—Prednisone—multiple sclerosis	0.00103	0.00132	CcSEcCtD
Nilutamide—Paraesthesia—Prednisone—multiple sclerosis	0.00102	0.00131	CcSEcCtD
Nilutamide—Pruritus—Triamcinolone—multiple sclerosis	0.00102	0.00131	CcSEcCtD
Nilutamide—Cough—Methotrexate—multiple sclerosis	0.00101	0.00131	CcSEcCtD
Nilutamide—Pruritus—Methylprednisolone—multiple sclerosis	0.00101	0.00131	CcSEcCtD
Nilutamide—Dyspepsia—Prednisone—multiple sclerosis	0.000998	0.00129	CcSEcCtD
Nilutamide—Chest pain—Methotrexate—multiple sclerosis	0.000989	0.00128	CcSEcCtD
Nilutamide—Decreased appetite—Prednisone—multiple sclerosis	0.000986	0.00127	CcSEcCtD
Nilutamide—Rash—Prednisolone—multiple sclerosis	0.000984	0.00127	CcSEcCtD
Nilutamide—Dermatitis—Prednisolone—multiple sclerosis	0.000983	0.00127	CcSEcCtD
Nilutamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00098	0.00126	CcSEcCtD
Nilutamide—Headache—Prednisolone—multiple sclerosis	0.000978	0.00126	CcSEcCtD
Nilutamide—Discomfort—Methotrexate—multiple sclerosis	0.000977	0.00126	CcSEcCtD
Nilutamide—Constipation—Prednisone—multiple sclerosis	0.00097	0.00125	CcSEcCtD
Nilutamide—Dizziness—Triamcinolone—multiple sclerosis	0.000949	0.00122	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	0.000947	0.00785	CbGpPWpGaD
Nilutamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000947	0.00122	CcSEcCtD
Nilutamide—Feeling abnormal—Prednisone—multiple sclerosis	0.000934	0.00121	CcSEcCtD
Nilutamide—Asthenia—Dexamethasone—multiple sclerosis	0.000934	0.00121	CcSEcCtD
Nilutamide—Asthenia—Betamethasone—multiple sclerosis	0.000934	0.00121	CcSEcCtD
Nilutamide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000927	0.0012	CcSEcCtD
Nilutamide—Nausea—Prednisolone—multiple sclerosis	0.000927	0.0012	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	0.000922	0.00764	CbGpPWpGaD
Nilutamide—Pruritus—Dexamethasone—multiple sclerosis	0.000921	0.00119	CcSEcCtD
Nilutamide—Pruritus—Betamethasone—multiple sclerosis	0.000921	0.00119	CcSEcCtD
Nilutamide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000916	0.00118	CcSEcCtD
Nilutamide—Vomiting—Triamcinolone—multiple sclerosis	0.000912	0.00118	CcSEcCtD
Nilutamide—Vomiting—Methylprednisolone—multiple sclerosis	0.00091	0.00118	CcSEcCtD
Nilutamide—Rash—Triamcinolone—multiple sclerosis	0.000905	0.00117	CcSEcCtD
Nilutamide—Dermatitis—Triamcinolone—multiple sclerosis	0.000904	0.00117	CcSEcCtD
Nilutamide—Anorexia—Methotrexate—multiple sclerosis	0.000903	0.00117	CcSEcCtD
Nilutamide—Rash—Methylprednisolone—multiple sclerosis	0.000903	0.00117	CcSEcCtD
Nilutamide—Dermatitis—Methylprednisolone—multiple sclerosis	0.000902	0.00116	CcSEcCtD
Nilutamide—Headache—Triamcinolone—multiple sclerosis	0.000899	0.00116	CcSEcCtD
Nilutamide—Headache—Methylprednisolone—multiple sclerosis	0.000897	0.00116	CcSEcCtD
Nilutamide—Abdominal pain—Prednisone—multiple sclerosis	0.000896	0.00116	CcSEcCtD
Nilutamide—Body temperature increased—Prednisone—multiple sclerosis	0.000896	0.00116	CcSEcCtD
Nilutamide—Diarrhoea—Betamethasone—multiple sclerosis	0.000891	0.00115	CcSEcCtD
Nilutamide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000891	0.00115	CcSEcCtD
Nilutamide—Dizziness—Dexamethasone—multiple sclerosis	0.000861	0.00111	CcSEcCtD
Nilutamide—Dizziness—Betamethasone—multiple sclerosis	0.000861	0.00111	CcSEcCtD
Nilutamide—Insomnia—Methotrexate—multiple sclerosis	0.000857	0.00111	CcSEcCtD
Nilutamide—Nausea—Triamcinolone—multiple sclerosis	0.000852	0.0011	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—multiple sclerosis	0.000851	0.0011	CcSEcCtD
Nilutamide—Nausea—Methylprednisolone—multiple sclerosis	0.000851	0.0011	CcSEcCtD
Nilutamide—Dyspnoea—Methotrexate—multiple sclerosis	0.000845	0.00109	CcSEcCtD
Nilutamide—Dyspepsia—Methotrexate—multiple sclerosis	0.000834	0.00108	CcSEcCtD
Nilutamide—Vomiting—Dexamethasone—multiple sclerosis	0.000828	0.00107	CcSEcCtD
Nilutamide—Vomiting—Betamethasone—multiple sclerosis	0.000828	0.00107	CcSEcCtD
Nilutamide—Decreased appetite—Methotrexate—multiple sclerosis	0.000824	0.00106	CcSEcCtD
Nilutamide—Rash—Dexamethasone—multiple sclerosis	0.000821	0.00106	CcSEcCtD
Nilutamide—Rash—Betamethasone—multiple sclerosis	0.000821	0.00106	CcSEcCtD
Nilutamide—Dermatitis—Betamethasone—multiple sclerosis	0.00082	0.00106	CcSEcCtD
Nilutamide—Dermatitis—Dexamethasone—multiple sclerosis	0.00082	0.00106	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000818	0.00106	CcSEcCtD
Nilutamide—Headache—Betamethasone—multiple sclerosis	0.000816	0.00105	CcSEcCtD
Nilutamide—Headache—Dexamethasone—multiple sclerosis	0.000816	0.00105	CcSEcCtD
Nilutamide—Asthenia—Prednisone—multiple sclerosis	0.000814	0.00105	CcSEcCtD
Nilutamide—Pain—Methotrexate—multiple sclerosis	0.00081	0.00105	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—CD4—multiple sclerosis	0.000809	0.00671	CbGpPWpGaD
Nilutamide—Pruritus—Prednisone—multiple sclerosis	0.000802	0.00104	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—MAPK1—multiple sclerosis	0.000794	0.00658	CbGpPWpGaD
Nilutamide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000781	0.00101	CcSEcCtD
Nilutamide—Diarrhoea—Prednisone—multiple sclerosis	0.000776	0.001	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000775	0.001	CcSEcCtD
Nilutamide—Nausea—Dexamethasone—multiple sclerosis	0.000773	0.000998	CcSEcCtD
Nilutamide—Nausea—Betamethasone—multiple sclerosis	0.000773	0.000998	CcSEcCtD
Nilutamide—Dizziness—Prednisone—multiple sclerosis	0.00075	0.000968	CcSEcCtD
Nilutamide—Abdominal pain—Methotrexate—multiple sclerosis	0.000749	0.000967	CcSEcCtD
Nilutamide—Body temperature increased—Methotrexate—multiple sclerosis	0.000749	0.000967	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000742	0.00615	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000742	0.00615	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000731	0.00606	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000731	0.00606	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000722	0.00599	CbGpPWpGaD
Nilutamide—Vomiting—Prednisone—multiple sclerosis	0.000721	0.000931	CcSEcCtD
Nilutamide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.00072	0.00597	CbGpPWpGaD
Nilutamide—Rash—Prednisone—multiple sclerosis	0.000715	0.000923	CcSEcCtD
Nilutamide—Dermatitis—Prednisone—multiple sclerosis	0.000714	0.000922	CcSEcCtD
Nilutamide—Headache—Prednisone—multiple sclerosis	0.00071	0.000917	CcSEcCtD
Nilutamide—Asthenia—Methotrexate—multiple sclerosis	0.00068	0.000878	CcSEcCtD
Nilutamide—Nausea—Prednisone—multiple sclerosis	0.000674	0.000869	CcSEcCtD
Nilutamide—Pruritus—Methotrexate—multiple sclerosis	0.00067	0.000865	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000662	0.00549	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000662	0.00549	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000653	0.00541	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000653	0.00541	CbGpPWpGaD
Nilutamide—Diarrhoea—Methotrexate—multiple sclerosis	0.000648	0.000837	CcSEcCtD
Nilutamide—Dizziness—Methotrexate—multiple sclerosis	0.000627	0.000809	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—STAT3—multiple sclerosis	0.000626	0.00519	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000605	0.00502	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000604	0.005	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000604	0.005	CbGpPWpGaD
Nilutamide—Vomiting—Methotrexate—multiple sclerosis	0.000603	0.000778	CcSEcCtD
Nilutamide—Rash—Methotrexate—multiple sclerosis	0.000598	0.000771	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—multiple sclerosis	0.000597	0.000771	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000595	0.00494	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000595	0.00494	CbGpPWpGaD
Nilutamide—Headache—Methotrexate—multiple sclerosis	0.000594	0.000766	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000571	0.00474	CbGpPWpGaD
Nilutamide—Nausea—Methotrexate—multiple sclerosis	0.000563	0.000727	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000546	0.00452	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ZNF746—multiple sclerosis	0.000541	0.00449	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PTBP1—multiple sclerosis	0.000495	0.0041	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000486	0.00403	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	0.00046	0.00382	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000416	0.00345	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000387	0.00321	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	0.00038	0.00315	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	0.000377	0.00312	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—STAT3—multiple sclerosis	0.000376	0.00312	CbGpPWpGaD
Nilutamide—AR—Gene Expression—HNRNPA1—multiple sclerosis	0.000375	0.00311	CbGpPWpGaD
Nilutamide—AR—Gene Expression—U2AF2—multiple sclerosis	0.000375	0.00311	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000346	0.00287	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PGR—multiple sclerosis	0.000339	0.00281	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000315	0.00261	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000314	0.0026	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ZFP36L1—multiple sclerosis	0.000296	0.00246	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000286	0.00237	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000285	0.00236	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000285	0.00236	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00028	0.00232	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000256	0.00212	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000254	0.00211	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000254	0.00211	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—VDR—multiple sclerosis	0.000237	0.00196	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000232	0.00192	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000232	0.00192	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PABPC1—multiple sclerosis	0.00023	0.00191	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.000229	0.0019	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000224	0.00186	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000208	0.00172	CbGpPWpGaD
Nilutamide—AR—Gene Expression—RPL5—multiple sclerosis	0.000207	0.00172	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.00019	0.00157	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000189	0.00157	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000185	0.00154	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SRM—multiple sclerosis	0.00018	0.00149	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000177	0.00146	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—multiple sclerosis	0.000168	0.00139	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—POMC—multiple sclerosis	0.000167	0.00138	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PGR—multiple sclerosis	0.000163	0.00135	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SRM—multiple sclerosis	0.000161	0.00133	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	0.000149	0.00123	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SRM—multiple sclerosis	0.000147	0.00121	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	0.000136	0.00113	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	0.000127	0.00105	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	0.000127	0.00105	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000124	0.00103	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GPC5—multiple sclerosis	0.000116	0.000962	CbGpPWpGaD
Nilutamide—AR—Gene Expression—VDR—multiple sclerosis	0.000114	0.000946	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	0.000113	0.000939	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	0.000113	0.000939	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000111	0.000917	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GPC5—multiple sclerosis	0.000104	0.000858	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	0.000103	0.000856	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	0.000103	0.000856	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000101	0.000836	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RRM1—multiple sclerosis	9.61e-05	0.000797	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GPC5—multiple sclerosis	9.44e-05	0.000783	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—multiple sclerosis	9.42e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RRM1—multiple sclerosis	8.58e-05	0.000711	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RRM1—multiple sclerosis	7.82e-05	0.000649	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.46e-05	0.000618	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.66e-05	0.000552	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.41e-05	0.000531	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.07e-05	0.000503	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.84e-05	0.000484	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.72e-05	0.000474	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—BCHE—multiple sclerosis	5.52e-05	0.000458	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.21e-05	0.000432	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.21e-05	0.000432	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—BCHE—multiple sclerosis	4.93e-05	0.000409	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.75e-05	0.000394	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—multiple sclerosis	4.53e-05	0.000376	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—BCHE—multiple sclerosis	4.49e-05	0.000372	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—APOE—multiple sclerosis	3.32e-05	0.000275	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—APOE—multiple sclerosis	2.96e-05	0.000246	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—POMC—multiple sclerosis	2.85e-05	0.000237	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—APOE—multiple sclerosis	2.7e-05	0.000224	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALB—multiple sclerosis	2.6e-05	0.000216	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—POMC—multiple sclerosis	2.55e-05	0.000211	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—POMC—multiple sclerosis	2.32e-05	0.000193	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALB—multiple sclerosis	2.32e-05	0.000192	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALB—multiple sclerosis	2.12e-05	0.000176	CbGpPWpGaD
